$90B by 2030
Regenerative medicine
Bioidentical ECM proteins as substrate, scaffold and delivery matrix for therapies that rebuild tissue.
Applications
How Jellatech can help
unlock human longevity.
The body is built from proteins. Making complex human proteins at scale is the missing step toward regenerative products that actually integrate with human biology.
$43B by 2030
Tissue engineering and scaffolds
Printable, gel-forming human proteins for constructs that need native sequence, folding and signaling.
$35B by 2030
Medical aesthetics and fillers
Next-generation regenerative injectables without animal immunogenicity or donor variability.
$19B by 2030
Advanced wound care
Matrices that stimulate endogenous collagen production and accelerate healing.
$20B by 2030
Cell therapy delivery
Carriers and scaffold chemistry for cell products where animal inputs are disqualifying.
$25B+ by 2030
Surgical and soft tissue repair
Matrices and coatings for repair products that must integrate with human tissue.
$85B by 2030
Topical cosmetics
Native human structural proteins for actives and formulations built on real protein, not fragments.
First protein
Human collagen type I is where we start.
Collagen type I is the most abundant protein in the human body and the structural foundation of skin, bone, tendon, blood vessels and connective tissue. It is also one of the hardest proteins to produce recombinantly because of its large size, triple helix folding and extensive post translational modifications.
We chose it first because solving collagen type I proves our platform can make complex human proteins that microbes and conventional expression systems cannot. It is the lead program, not the end of the platform.
What is collagen type I
The scaffold the body is built on.
Where it works
Type I collagen is the main structural protein in skin, bone, tendon, ligaments, blood vessels and the extracellular matrix. It gives tissues shape, strength and elasticity.
How it is built
Three procollagen chains wind into a triple helix, then assemble into fibrils and fibers. This structure requires specific hydroxylation and folding that only human cells perform correctly.
Why it matters
As we age, collagen production slows while degradation accelerates. The result is weaker skin, slower wound healing, fragile joints, brittle bone and loss of tissue structure. Native human collagen is the direct replacement.
Beyond collagen
Type I collagen is the first product, not the platform.
What we built is a human cell platform for making large, complex, correctly folded human proteins. Collagen type I is the hardest version of that problem and our lead product, which is why we started there.
The same cell lines, cultivation and purification workflow extend to other collagen types, extracellular matrix and structural proteins, and growth factors and other multi-domain human proteins that microbial systems cannot assemble. Each new protein is a new program on the same platform, not a new company.
Discuss a protein program